Lexeo Therapeutics, Inc. (NasdaqGM: LXEO)
Health Care · Biotechnology · US
$3.23
-8.50% today · -60.6% 1Y
Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $265.00M and employs 63 people.
Over the last twelve months the share price has lost 60.6%, trading between 2.98 and 10.99.
Tweenvest scores Lexeo Therapeutics, Inc. across four factors: quality 36/100, value 34/100. Its strongest factor is quality.
LXEO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $265.00M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.15
- Dividend yield
- —
- Beta (5Y)
- 1.64
- 52-week high
- $10.99
- 52-week low
- $2.98
- Avg volume (3M)
- —
- Shares outstanding
- 82.04M
- Employees
- 63
- Next earnings
- —
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
- ISIN
- US52886X1072
- Founded
- 2017
- Listed since
- Nov 3, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Northwest Biotherapeutics, Inc.OTCPK: NWBO | $267.79M | $0.16 | +2.15% |
| Century Therapeutics, Inc.NasdaqCM: IPSC | $266.18M | $1.47 | -3.92% |
| Mabpharm LimitedSEHK: 2181 | $265.39M | HK$0.51 | +3.06% |
| BridgeBio Oncology Therapeutics, Inc.NasdaqGM: BBOT | $265.38M | $3.31 | -14.91% |
| Inventage Lab, Inc.KOSDAQ: A389470 | $263.31M | ₩26,600.00 | -6.01% |
| Santhera Pharmaceuticals Holding AGSWX: SANN | $263.01M | CHF14.28 | -5.56% |
| Obigen Pharma Inc.TPEX: 7876 | $262.25M | NT$78.20 | +21.81% |
| Anika Therapeutics, Inc.NasdaqGS: ANIK | $262.04M | $19.58 | +1.82% |
Figures last refreshed Oct 11, 2026.